Cargando…
RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif
RebiQoL was a phase IV multicenter randomized study to assess the impact of a telemedicine patient support program (MSP) on health-related quality of life (HRQoL) in patients with relapsing-remitting MS (RRMS) being administered with Rebif with the RebiSmart device. The primary endpoint was to asses...
Autores principales: | Landtblom, Anne-Marie, Guala, Dimitri, Martin, Claes, Olsson-Hau, Stefan, Haghighi, Sara, Jansson, Lillemor, Fredrikson, Sten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611587/ https://www.ncbi.nlm.nih.gov/pubmed/31276502 http://dx.doi.org/10.1371/journal.pone.0218453 |
Ejemplares similares
-
Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008) -
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon
por: Zare, Nasrin, et al.
Publicado: (2013) -
Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis
por: Sauri-Suárez, Sergio, et al.
Publicado: (2020) -
An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device
por: Willis, Helen, et al.
Publicado: (2014) -
Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
por: Fernández, O., et al.
Publicado: (2016)